SKF 81297 hydrobromideD1 agonist CAS# 67287-39-2 |
- SB202190 (FHPI)
Catalog No.:BCC1093
CAS No.:152121-30-7
- SB 239063
Catalog No.:BCC1923
CAS No.:193551-21-2
- SD-06
Catalog No.:BCC1937
CAS No.:271576-80-8
- BIRB 796 (Doramapimod)
Catalog No.:BCC2535
CAS No.:285983-48-4
- LY2228820
Catalog No.:BCC2528
CAS No.:862507-23-1
Quality Control & MSDS
Number of papers citing our products
Chemical structure
3D structure
Cas No. | 67287-39-2 | SDF | Download SDF |
PubChem ID | 11957706 | Appearance | Powder |
Formula | C16H17BrClNO2 | M.Wt | 370.67 |
Type of Compound | N/A | Storage | Desiccate at -20°C |
Solubility | Soluble to 100 mM in DMSO and to 10 mM in water | ||
Chemical Name | 9-chloro-5-phenyl-2,3,4,5-tetrahydro-1H-3-benzazepine-7,8-diol;hydrobromide | ||
SMILES | C1CNCC(C2=CC(=C(C(=C21)Cl)O)O)C3=CC=CC=C3.Br | ||
Standard InChIKey | RMIJGBMRNYUZRG-UHFFFAOYSA-N | ||
Standard InChI | InChI=1S/C16H16ClNO2.BrH/c17-15-11-6-7-18-9-13(10-4-2-1-3-5-10)12(11)8-14(19)16(15)20;/h1-5,8,13,18-20H,6-7,9H2;1H | ||
General tips | For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for several months. We recommend that you prepare and use the solution on the same day. However, if the test schedule requires, the stock solutions can be prepared in advance, and the stock solution must be sealed and stored below -20℃. In general, the stock solution can be kept for several months. Before use, we recommend that you leave the vial at room temperature for at least an hour before opening it. |
||
About Packaging | 1. The packaging of the product may be reversed during transportation, cause the high purity compounds to adhere to the neck or cap of the vial.Take the vail out of its packaging and shake gently until the compounds fall to the bottom of the vial. 2. For liquid products, please centrifuge at 500xg to gather the liquid to the bottom of the vial. 3. Try to avoid loss or contamination during the experiment. |
||
Shipping Condition | Packaging according to customer requirements(5mg, 10mg, 20mg and more). Ship via FedEx, DHL, UPS, EMS or other couriers with RT, or blue ice upon request. |
Description | Dopamine D1-like receptor agonist. Centrally active following systemic administration in vivo. |
SKF 81297 hydrobromide Dilution Calculator
SKF 81297 hydrobromide Molarity Calculator
1 mg | 5 mg | 10 mg | 20 mg | 25 mg | |
1 mM | 2.6978 mL | 13.4891 mL | 26.9782 mL | 53.9563 mL | 67.4454 mL |
5 mM | 0.5396 mL | 2.6978 mL | 5.3956 mL | 10.7913 mL | 13.4891 mL |
10 mM | 0.2698 mL | 1.3489 mL | 2.6978 mL | 5.3956 mL | 6.7445 mL |
50 mM | 0.054 mL | 0.2698 mL | 0.5396 mL | 1.0791 mL | 1.3489 mL |
100 mM | 0.027 mL | 0.1349 mL | 0.2698 mL | 0.5396 mL | 0.6745 mL |
* Note: If you are in the process of experiment, it's necessary to make the dilution ratios of the samples. The dilution data above is only for reference. Normally, it's can get a better solubility within lower of Concentrations. |
Calcutta University
University of Minnesota
University of Maryland School of Medicine
University of Illinois at Chicago
The Ohio State University
University of Zurich
Harvard University
Colorado State University
Auburn University
Yale University
Worcester Polytechnic Institute
Washington State University
Stanford University
University of Leipzig
Universidade da Beira Interior
The Institute of Cancer Research
Heidelberg University
University of Amsterdam
University of Auckland
TsingHua University
The University of Michigan
Miami University
DRURY University
Jilin University
Fudan University
Wuhan University
Sun Yat-sen University
Universite de Paris
Deemed University
Auckland University
The University of Tokyo
Korea University
- Cabraleadiol
Catalog No.:BCN4224
CAS No.:67253-01-4
- Boc-MLF
Catalog No.:BCC6061
CAS No.:67247-12-5
- 10(14)-Cadinene-4,5-diol
Catalog No.:BCN4223
CAS No.:672336-50-4
- Fenoldopam
Catalog No.:BCC4462
CAS No.:67227-56-9
- 5'-O-Dimethoxytrityl-N-benzoyl-desoxycytidine
Catalog No.:BCC8750
CAS No.:67219-55-0
- 2'-O-Coumaroyljuglanin
Catalog No.:BCN6559
CAS No.:67214-05-5
- SMER 3
Catalog No.:BCC6152
CAS No.:67200-34-4
- H-HoSer-OH
Catalog No.:BCC3247
CAS No.:672-15-1
- (±)-U-50488 hydrochloride
Catalog No.:BCC6665
CAS No.:67197-96-0
- Moronic acid
Catalog No.:BCN4222
CAS No.:6713-27-5
- Yamataimine
Catalog No.:BCN2064
CAS No.:67113-69-3
- Tubotaiwine
Catalog No.:BCN4016
CAS No.:6711-69-9
- SKF 83959 hydrobromide
Catalog No.:BCC7251
CAS No.:67287-95-0
-
γDGG
Catalog No.:BCC6557
CAS No.:6729-55-1
- Kif15-IN-1
Catalog No.:BCC5152
CAS No.:672926-32-8
- Kif15-IN-2
Catalog No.:BCC5153
CAS No.:672926-33-9
- 3-O-(2'E ,4'Z-decadienoyl)-20-deoxyingenol
Catalog No.:BCN1382
CAS No.:672941-64-9
- Kansuinine E
Catalog No.:BCN3769
CAS No.:672945-84-5
- H-D-Phe-OH
Catalog No.:BCC3012
CAS No.:673-06-3
- H-Asp(OtBu)-OMe.HCl
Catalog No.:BCC2892
CAS No.:2673-19-0
- 2-Hydroxy-4-methoxybenzaldehyde
Catalog No.:BCN7798
CAS No.:673-22-3
- Kaurenoic acid
Catalog No.:BCN4600
CAS No.:6730-83-2
- 1,3,5-Trihydroxyxanthone
Catalog No.:BCN3357
CAS No.:6732-85-0
- Hexa-D-arginine
Catalog No.:BCC6269
CAS No.:673202-67-0
Pharmacological characterization of the discriminative stimulus properties of the dopamine D1 agonist, SKF 81297.[Pubmed:11224180]
Behav Pharmacol. 1993 Apr;4(2):135-146.
A range of selective dopamine D1 and D2 receptor agonists and antagonists was used to characterize to the discriminative stimuli produced by d-amphetamine (0.5mg/kg) and the D1 agonists SKF 81297 (0.1mg/kg). In rats trained to discriminate d-amphetamine (0.5mg/kg) from saline, d-amphetamine produced a dose-related increase in per cent drug lever responding, and SKF 81297 did not show any d-amphetamine-like discriminative stimulus effects; neither did SKF 81297 potentiate nor antagonize the d-amphetamine discriminative stimulus. In rats trained to discriminate SKF 81297 (0.1mg/kg) from saline, SKF 81297 produced a dose-related increase in per cent drug lever responding, and SKF 38393 and SKF 83565 elicited full SKF 81297-like effects despite the fact that these compounds have widely differing efficacies for stimulating adenylate cyclase. SKF 81297 had a 25-fold greater potency than SKF 38393 in this assay. The D2 agonists, PHNO and ropinirole, did not display any SKF 81297-like discriminative stimulus effects. The SKF 81297 discriminative stimulus was completely blocked by the D1 antagonist SCH 23390 but was not blocked by the D2 antagonist BRL 34778.
The effects of dopamine D1 and D2 receptor agonists and antagonists in monkeys withdrawn from long-term neuroleptic treatment.[Pubmed:1980891]
Eur J Pharmacol. 1990 Sep 4;186(1):49-59.
The effects of dopamine D1 and D2 receptor agonists and antagonists were studied in eight Cebus apella monkeys previously treated with haloperidol for two years. SKF 81297 (specific D1 receptor agonist) induced oral hyperkinesia of variable intensity (P less than 0.01): some of the monkeys developed extreme lip smacking, tonque protrusions and licking movements while others developed only slight lip movements. A combined treatment of SKF 81297 with LY 171555 (full D2 receptor agonist) or SCH 23390 (D1 receptor antagonist) inhibited the oral hyperkinesia induced by SKF 81297 (P less than 0.01, P less than 0.02, respectively). Raclopride (D2 receptor antagonist) did not statistically change oral hyperkinesia (P less than 0.2), although five monkeys showed increased oral movements; most of these monkeys had pre-existing hyperkinesia. Treatment with SCH 23390 or raclopride resulted in an identical dystonic/cataleptic syndrome. SKF 81297 inhibited the dystonia induced by SCH 23390, while it did not significantly affect raclopride dystonia. The investigation indicates that oral dyskinesia may be related to an imbalance in D1 receptor and D2 receptor stimulation in favor of D1 receptors. The question now is whether D1 receptor antagonists, which may have antipsychotic potential, will produce tardive dyskinesia after long-term use.
Relative dopamine D1 and D2 receptor affinity and efficacy determine whether dopamine agonists induce hyperactivity or oral stereotypy in rats.[Pubmed:3259694]
Pharmacol Toxicol. 1988 Mar;62(3):121-30.
The effects of a range of dopamine (DA) agonists on stereotyped behaviour in rats were analysed and compared both with the affinity of the compounds for D1 and D2 receptor binding sites in vitro and their ability to stimulate the adenylate cyclase activity in rat striatal homogenates. Full and partial agonists at the D1 receptor coupled to adenylate cyclase do not induce sterotypies when given alone, whereas full D2 agonists (e.g. quinpirole) induce hyperactivity but not oral sterotypies. Partial D2 agonists (e.g. (-)-3-PPP) only induce sedation. Mixed D1/D2 agonists (e.g. apomorphine) induce both hyperactivity and oral stereotypies. Maximum stereotypies were induced by combination of SK & F 38393 and a series of D2 agonists, including full agonists and the partial D2 agonist B-HT 920, whereas partial agonists with low intrinsic activity (e.g. (-)-3-PPP, EMD 23448) did not induce stereotypies when given together with SK & F 38393. However, these partial agonists reduced the maximum effect of apomorphine, whereas the full agonists (e.g. quinpirole, (-)-NPA) and B-HT 920 had no apomorphine antagonistic activity. The mixed D1/D2 agonists apomorphine and N,N-dipropyl-5,6-ADTN were only weakly influenced by SK & F 38393, or not at all. D1 agonists with central effects, including SK & F 38393, SK & F 81297 (with relatively high efficacies), and the partial agonist SK & F 75670 with low efficacy, changed the hyperactivity induced by quinpirole into maximum oral stereotypy, whereas the peripheral D1 agonist fenoldopam had no such effect. Inhibition of DA and NA synthesis with alpha-methyl-p-tyrosine depleted striatal DA levels by 72 per cent and antagonized the hyperactivity induced by the D2 agonists quinpirole and (-)-NPA, but not that of apomorphine. Combination of SK & F 38393 and quinpirole induced maximum stereotypy in DA-depleted animals. These results suggest that D1 receptor tonus is a necessary prerequisite for the expression of a DA agonist's effect. The hyperactivity induced by full D2 agonists appears to be mediated by D1 tonus provided by endogenous DA activity, but stronger D1 stimulation is necessary to induce oral stereotypy. A high degree of D1 receptor activation increases the ability of partial D2 agonists to induce hyperactivity or oral stereotypies since treatment with both SK & F 38393 and B-HT 920 had marked effects while B-HT 920 was ineffective.(ABSTRACT TRUNCATED AT 400 WORDS)